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Objective: Determine reliability and basic psychometric properties of a composite cognitive endpoint, MS-COG,
for monitoring change in cognitive function in MS drug trials.
Background: 50% of MS patients have cognitive impairment that impacts ability to work and quality of life. We
selected neuropsychological tests based on sensitivity to MS cognitive impairment, availability of alternate
forms, cross-cultural utility, and feasibility for multicenter trials, and assessed the reliability and validity of a
composite endpoint, MS-COG.
Design/methods: Administered SRT, BVMT-R, PASAT, and SDMT to 60 MS patients at 4 US centers twice over
45 days, along with symptom inventories by patients and informants.
Results: The MS-COG had test–retest reliability of 0.91. Processing Speed and Memory indices had reliabilities of
0.89 and 0.86, withmodest practice effects. Reliability was high for the RRMS and SPMS subgroups aswell, with
correlations of .90 and .93, respectively for MS-COG. Overall, 42% of subjects obtained MS-COG scores in the im-
paired range,with SPMS subjects performing 0.8 SDbelowRRMS subjects. Impairment correlatedwell (r=0.37
to 0.40) with informant reports but was inconsistent with patient report, with the least reliable assessments by
those with greater symptom severity.
Conclusions: The MS-COG is a reliable, repeatable measure of MS cognitive functioning that is sensitive to cogni-
tive impairment in SP MS and RRMS patients and feasible for multicenter clinical trials. Further development is
warranted.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cognitive Impairment Associated with Multiple Sclerosis (CIAMS)
[1] is common, with frequencies ranging from 40 to 75% reported in
clinical samples [2–5] andmeta-analyses [6–10], with estimates varying
according to the deﬁnition of cognitive impairment. Processing Speed
and Learning/Memory are the domains identiﬁed as most likely to be
impaired in individual MS subjects with frequency rates estimated at
approximately 52% and 54%, respectively, [11,12] with impairment in
each domainmanifesting at differing levels of severity within individual
patients [13]. These cognitive impairments are relatively independentB, New York, NY 10065, United
ger).
. This is an open access article underof MS symptoms that cause motor impairment [6,14] and comprise a
signiﬁcant contributing factor to overall disability and lessened quality
of life [15]. A pharmaceutical therapy that improves cognitive function-
ing inMS patients would therefore be of considerable value in the over-
all management of MS. However, in order to assess the effectiveness of
pharmaceutical interventions, reliable and valid indices of meaningful
cognitive change that are feasible for multicenter clinical trials are
required.
The present study sought to determine the reliability of a composite
endpoint (MS-COG) for use in determining efﬁcacy of diseasemodifying
pharmaceutical agents in the improvement of cognitive functioning in
MS patients. An a priori composite endpoint merits investigation as
similar composite endpoints for other disease entities that have been
required by FDA in past trials [16–18]. In addition, a composite endpointthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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improved reliability, and greater simplicity in summarizing treatment
effects and relating clinical meaningfulness of the observed changes
[16–19]. There are, of course, disadvantages in collapsing multiple do-
mains into a single endpoint, including potentially decreased sensitivity
in comparison to a single endpoint and greater difﬁculty in interpretation
of any change identiﬁed. In regard to the former, when a pharmaceutical
agent aims to improve cognitive functioning generally, focus on change in
an individual domain may potentially disproportionally represent
improvement in a given subject if such gains are not present in other
domains. We therefore recommended combining multiple domains in
a single endpoint. In regard to the latter, clinical interpretation of the
composite endpoints will still require scrutiny of the underlying factors.
Although there have been a number ofMS studies examining poten-
tial improvement due to the effects of a pharmaceutical agent on indi-
vidual tests of cognitive functioning over the course of a trial [20–22],
little research has been published examining the effects of such an
agent on general neuropsychological test performance in MS. An earlier
investigation by Fischer et al. [23] examined the effects of intramuscular
interferon beta-1a (Avonex®) in MS patients using a comprehensive
neuropsychological test battery administered over a 2 year time span
in a subset of English speaking subjects from the Phase 3 registrational
clinical trial (MSCRG study). Tests measuring Learning, Memory, and
Processing Speed were group together post hoc as being the most fre-
quently impaired domains. A signiﬁcant improvement of approximately
0.5 standard deviations was identiﬁed for Avonex over placebo. Subse-
quent efforts by Rao [24] and Benedict et al. [25] demonstrated that
briefer assessments than used by Fischer et al. might be useful for
identifying cognitive impairment inMS, but their operational feasibility
has limited their use in drug trials.
The current project began when Biogen Idec recruited a panel of
advisors with extensive experience in research on cognitive impairment
in MS clinical pharmaceutical research populations (authors DE, RB, FF,
JW, and JD). In recommending tests for the current research, the advisory
panel considerednot only the sensitivity of the proposed component tests
to MS impairment, but also test–retest reliability, the availability
of multiple alternate forms for longitudinal studies, suitability for
administration by newly trained clinical staff, and the feasibility for use
in cross-cultural and linguistic settings. In considering these factors, the
expert panel chose the Paced Auditory Serial Addition Test (PASAT) [24,
26], Selective Reminding Test (SRT) [27], Symbol Digit Modalities Test
(SDMT) [24,28], and Brief Visuospatial Memory Test — Revised (BVMT-
R) [29] to cover the two cognitive domains most affected inMS, informa-
tion processing (PASAT and SDMT) and Learning and Memory (SRT and
BVMT-R). Notably, these testswere identiﬁedby Strober et al. [30] as hav-
ing optimal sensitivity to detect impairment in the MS population, with
effect sizes ranging from d= 0.7 to d = 1.1, which was not the case for
tests of other domains included in previous MS Cognitive Batteries such
as executive functions, language, and visuospatial judgment [31].
The current study sought to establish the basis for combining
the neuropsychological measures selected by the expert panel into a
single endpoint, the MS-COG, for use in pharmaceutical research, and
determine basic psychometric properties related to reliability. An inves-
tigation of the relationship of the endpoint to the observations of the
patient and their designated caregiver on real world cognitive function
was also investigated.
2. Methods
2.1. Participants
Subjects were recruited from existing patient lists from four MS cen-
ters in the United States, each recruiting 15 patients with documented
history of Relapsing–Remitting (RR) or Secondary Progressive (SP) MS.
Participants who agreed to enroll were paid $60. Participants were in-
cluded regardless of MS severity, presence of cognitive impairment, orduration of illness so as to be representative of MS clinic patients gener-
ally. Exclusion criteria included physical or sensory impairment that
might preclude completion of cognitive test protocols, untreated major
depressive and/or untreated anxiety disorder of sufﬁcient severity to po-
tentially to impact cognitive skills, history of severe psychiatric illness
such as bipolar disorder or schizophrenia, or severe traumatic brain inju-
ry or othermedical illnesses that would preclude valid completion of the
assessments. One subject was excluded after enrolment because of the
onset of clinically signiﬁcant symptoms of depression following Study
Day 1 andwhichwere of sufﬁcient severity such that the subject was un-
able to travel to the research site. All other patients were neurologically
and psychiatrically stable for the duration of the study.
Demographic characteristics of the sample identiﬁed the group as
typical of clinicalMSpopulations [12] aswell as of populations recruited
for pharmaceutical studies [22]. The groupwas comprised of 43women
(72%) and 16men (28%) recruited from lists of patients diagnosed with
MS according toMcDonald criteria in 4U.S. clinics,with an average age of
47.9 (SD = 7.9; range = 26–61). A majority (77%) were receiving dis-
ease modifying therapy. Average time since diagnosis was 13.2 years
(SD = 8.5; range = 1–33). Similar to reported studies of other clinical
MS populations, the majority (87%) were Caucasian, with 5% identifying
as African-American, 5% as Hispanic, and 3% as other; only 2% were not
high school graduates, with 27% having a high school degree or GED,
18% an Associate Degree, 28% a Bachelors Degree, 21% a Masters Degree
and 5% an advanced degree; themedian ExpandedDisability Status Scale
(EDSS) [32] was 2.5 and the mode was 2; approximately 77% of partici-
pants had a diagnosis of RR MS and 23% one of SP MS; [12,24,33]. As
might be expected, the group diagnosed with SP MS was signiﬁcantly
older than that of patients with RR MS (55.1 ± 5.6 years vs. 47.9 ±
9.2 years) and had signiﬁcantly higher EDSS ratings (4.2 ± 1.8 vs. 2.2
± 1.5). The groups did not differ in regard to education or ethnicity.
2.2. Procedures
Participants were assessed at two time points, approximately 45
days apart. Each participant completed the SDMT Oral Version, PASAT,
BVMT-R, and SRT on each occasion. A 45 day retest interval was chosen
based on clinical observations that this was sufﬁcient for identiﬁcation
of change on measures of memory in a prior MS study [22,34]. Order
of test administration was as follows: SRT and BVMT-R Learning Trials,
SDMT, PASAT 3- and 2-second trials, SRT Delayed Recall, BVMT-R De-
layed Recall. Total time for administration was approximately 30 min.
Equivalent alternate forms were used to minimize form-speciﬁc prac-
tice effects. Self-report forms—the Multiple Sclerosis Quality of Life-54
(MSQOL-54: cite), the Memory Functioning Questionnaire (MFQ) [35]
and the Multiple Sclerosis Neuropsychological Questionnaire-Patient
(MSNQ-P) [36,37] were administered prior to the neuropsychological
tests in order to limit the degree to which a subject based her/his opin-
ion on test performances. The Multiple Sclerosis Neuropsychological
Questionnaire-Informant (MSNQ-I) [36,37] as completed at the conve-
nience of the caregiver without knowledge of actual test performance
and returned to the investigator.
2.3. MS-COG test instruments
2.3.1. Symbol Digit Modalities Test (SDMT)
In this measure of Processing Speed and Working Visual Memory,
the subject is given 90 s to pair speciﬁc numbers with given geometric
ﬁgures based on a reference key using an oral response, to limit prob-
lems due to dexterity in MS patients [24]. At Study Day 1 the original,
WPS-published form was administered [28] and at Visit 2 Rao’s Form
2 [38] was administered.
2.3.2. Paced Auditory Serial Addition Test (PASAT)
First developed by Gronwall to assess patients recovering from
concussion [39], the PASAT requires patients to monitor a series of 61
Table 1
Average performances, frequency of cognitive impairment, and test–retest reliability of
individual measures.
Measure N Mean Z score % b −1.5 SD Pearson R
SDMT 59 −1.1 36 .89
PASAT 3 59 −0.70 27 .85
PASAT 2 58 −0.62 26 .87
SRT Total 59 −0.75 29 .70
SRT Delay 59 −0.80 34 .62
BVMT-R Total 59 −1.3 53 .82
BVMT-R Delay 59 −1.7 54 .83
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diately preceding it. The numbers of intervals and presentation rates
were subsequently modiﬁed by Rao [38] calling for two trials, with
inter-stimulus intervals of 3 and 2 s, respectively. Rao's Forms A and B
were administered at Study Days 1 and 2, respectively.2.3.3. Selective Reminding Test
The history of this test begins with the work of Buschke and Fuld
who conducted research in the area of anterograde amnesia [27]. After
the examiner reads a list of 12 target words on an initial learning trial,
the test-taker is asked to try to repeat the entire list. On 5 subsequent
learning trials, the SRT requires the experimenter to repeat only target
words not recalled by the subject on the previous trial, and test-taker
is asked to repeat the entire list. A Delayed Recall trial is included.
Hannay and Levin's word lists for adults, Forms 1 and 3, were selected
for this study based on available research demonstrating equivalence
in difﬁculty [40].2.3.4. Brief Visuospatial Memory Test — Revised
The Brief Visuospatial Memory Test— Revised (BVMT-R) is based on
an initial effort to develop equivalent alternate form Visual Memory
tests [41,42]. In the revised version [29,43], the BVMT-R includes three
10-s exposures to the stimulus. After each exposure, the subject is
asked to reproduce the matrix with using a pencil on a blank sheet of
paper. Further, there is extensive research showing that all 6 forms of
the test are of equivalent difﬁculty. Variables of interest in the current
study were the Total Learning and Delayed Recall scores. In the current
study, Forms 1 and 4were utilized based on the recommendation of the
test author (RB) and his knowledge of the research on this measure.2.3.5. Memory Functioning Questionnaire
TheMemory Functioning Questionnaire [44] was designed to exam-
ine self-reported memory complaints. It consists of 64 items addressing
memory difﬁculty and frequency of forgetting, presented in 7 sections,
each rated on a 7-point scale.SRT
Learning
SRT
Delay
BVMT-R
Learning
Memory
Fig. 1.MS-COG c2.3.6. MS Neuropsychological Questionnaire
TheMSNQ [36] is a 15-item report schedulewith versions developed
both for patient- and informant-reports of cognitive and neuropsychiat-
ric symptoms commonly observed in the MS population.
2.3.7. MS Quality of Life-54
The MSQOL-54 was developed by combining the most widely
utilized generic measure of quality of life in the world, the SF-36, with
additional items speciﬁc to MS.
2.4. Data analyses
Analyses were completed using SPSS software. All subjects
who completed both visits were included in all data analyses. Of these
subjects, data for the PASAT 2″ trialwas not available for one participant
not completing the procedure at the initial visit after becoming
overly frustrated. All raw scores were converted into demographically
adjusted z scores using peer-reviewed control data from subjects [30]
similar in age, gender and education to the current study group, recruit-
ed through newspaper advertisements for a differentMS study [30]. For
the purposes of the current study in which correlations among tests
were of interest, it was decided that using control data from a group ad-
ministered all of the same tests was preferable to use of disparate nor-
mative databases, despite the limitations of using this relatively small
comparison group. Indeed, future research plans include compilation
of a larger comparison group of healthy subjects. Z scores were used
for all analyses. Reliability was investigated using Pearson r correlations
and intraclass correlations. Qualitative characterization of reliabilities is
discussed below in keeping with Slick [45]. A priori assumptions based
on existing literature [12,46] that PASAT and SDMT could be combined
into a Processing Speed factor and that SRT and BVMT-R could be com-
bined into a Learning andMemory Factorwere examinedusing loadings
on factor analysis as detailed below. The factors andMS-COG per sewere
constructed according to clinical usage as detailed below. An a priori
cutoff of .70 was established as indicative of minimally acceptable
reliability [47]. Exploratory analyses using Pearson r correlations were
conducted to examine the associations among the composite endpoint
and the self- and informant-report scales.
3. Results
The population was similar in demographic characteristics to the
normative control data [30] used to generate the standard scores, with
the respective groups comprised of 72 vs. 84% women with mean age
of 47.9 vs. 45.2 years and mean education of 15 years for each group.
Subjects were re-tested 28 to 58 days after the initial assessment with
a mean interval of 42.7 ± 6.8 days. The individual neuropsychological
measures each revealed sensitivity to cognitive impairment in this
clinical sample. Standardized summary scores for cognitive indicesBVMT-R
Delay
PASAT 3”
and 2” SDMT
Information
Processing Speed
Total
Composite
onstruction.
Table 2
Rotated Component Matrix— Principal Component Analysis, Rotation Method: Varimax
with Kaiser normalization.
Factor Component
1 2
SDMT 0.586 0.567
PASAT 3″ 0.308 0.891
PASAT 2″ 0.178 0.942
SRT Learning 0.744 0.420
SRT Delayed Recall 0.831 0.099
BVMT-R Total Learning 0.854 0.280
BVMT-R Delayed Recall 0.817 0.295
Table 4
Reliability for factor scores and the MS-COG.
Index Pearson r ICC
Learning and Memory Factor .86 .86
Information Processing Speed Factor .89 .90
MS-COG .91 .90
Table 5
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based on that researcher's normative control data which included all
the measures of interest. Average performance across subtests was
well below the control z score mean of 0 and ranged from −0.62 to
−1.7. Prevalence of impairment as deﬁned by a score of−1.5 below
the controlmeanor greater ranged from26% to 54%. Test–retest reliabil-
ities for the individual measures ranged from .63 to .89 with stronger
correlations associated with speeded measures in comparison to those
of Learning and Memory (Table 1).
The standardized summary scores were entered into a factor analy-
sis. Eigenvalues of 4.43 and 1.04 identiﬁed two factors accounting for a
total of 78% of the variance. All combinations of estimation method
(principal axis factoring, maximum likelihood), rotation procedure
(orthogonal vs. oblique), and extraction criteria (all factors with eigen-
values N1 vs. only the ﬁrst two factors) were explored in order to
explore the stability of the factors analysis. As illustrated in Table 2,
varimax rotation with Kaiser normalization identiﬁed Factor 1 as com-
prised of loadings of SRT Total Learning and Delayed Recall, BVMT-R
Total Learning and Recall, and SDMT with loadings ranging from 0.59
to 0.85. Factor 2 was comprised of SDMT, PASAT 3″ and PASAT 2″with
loadings ranging from 0.57 to 0.95. These factors were labeled Learning
and Memory (LM) Factor and Information Processing Speed (IPS) Fac-
tor, accordingly.
Construction of the LM composite was accomplished by averaging
the standard scores for the 4 component indices, thus giving equal
weightings both to Verbal and Visual Memory as well as both to Learn-
ing and Delayed Recall scores. This plan was in keeping with each indi-
ces' roughly equivalent sensitivity to cognitive impairment in MS
patients as detailed by Strober et al. [30]. For the IPS composite, the
two PASAT total scores were averaged and then combined with the
SDMT, so as to give equal weightings to these different paradigms as
well as to reﬂect Strober et al.'s ﬁnding that the SDMT has relatively
greater sensitivity to cognitive impairment. TheMS-COGwas construct-
ed by averaging the LM and IPS composites with equal weighting. This
methodology is diagramed in Fig. 1.
The sensitivity of the LM and IPS composites and MS-COG to
impairment was evident in mean scores ranging from z = −1.14
to z = −1.19, with the frequency of impairment being comparable
to the numerous studies discussed above (Table 3). Inspection of im-
pairment within vs. across domain indicated that although a total of
54% of the sample was impaired in either IPS or LM, 42% was impaired
in both IPS and LM. Notably, the participants impaired in both domains
were the same as those identiﬁed as impaired by MS-COG. MS-COG,
therefore, appeared to have a considerable advantage in identifyingTable 3
Severity and frequency of impairment for factor scores and MS-COG.
Factor N Mean Z score % b −1.5 SD
Information Processing Speed 58 −1.19 40
Learning and Memory 59 −1.15 39
MS-COG 58 −1.14 42participants with a cognitive impairment syndrome in comparison to
individual domains. (See Table 2.)
Reliability of the factor scores and the MS-COG were all considered
high with Pearson r and intraclass correlations ranging from .86 to .91
as reported in Table 4.
Psychometric characteristics of the MS-COG score are reported in
Table 5. As illustrated, the MS-COG showed good sensitivity to impair-
ment as indicated by the mean z score of−1.1 at Visit 1 and was nor-
mally distributed, without signiﬁcant skewness or kurtosis. A practice
effect of 0.35 SD ((32% improvement) was evident at Visit 2, although
the high reliability demonstrated by the MS-COG indicates that this is
not an obstacle to detecting change in cognitive functioning in a longitu-
dinal clinical trial, particularly as there was no evidence of a ceiling
effect. Moreover, this retest effect is consistent with similar effects pre-
viously reported for these measures [48].
We calculated standard errors of difference and retest effects forMS-
COG and the factor scores to facilitate clinical decision making. These,
along with cutoff scores for identifying decline with 80% and 90%
conﬁdence are provided in Table 6. Clinicians would calculate scores
as follows: (score at time 2 − (score 1 + retest effect)) / S diff = z.
Any z score below − .83 and −1.26 would be indicative of decline
with 80% and 90% conﬁdence, respectively.
To examine the ability of the MS-COG to detect cognitive impair-
ment in MS, severity and frequency of impairment were compared
across the Relapsing–Remitting and Secondary Progressive MS
subgroups. As would be expected, those participants with Secondary
Progressive MS have cognitive impairment of greater severity and
were more frequently impaired on both composite domains and on
the MS-COG as shown in Table 7.
Reliability scores according to MS subtype were all high, with
Secondary Progressive participants demonstrating marginally greater
reliabilities generally as shown in Table 8.
Pearson r correlations were performed to explore the associations
between objective performance on standardized tests of cognitive func-
tion (MS-COG) and the self- and informant reported symptoms of cog-
nitive impairment. None of the correlations were strong (Table 9). The
hypothesized directions of the MFQ and MSQOL instruments were in
the positive direction and that of the MSNQ in the negative direction.
The strength and directionality of the associations differed according
to MS type, with stronger correlations for reports of RR MS patients
than of SPMS patients. Informant reports weremore consistent regard-
less of MS type. Table 9 contains the ﬁndings for these subgroups.
4. Discussion
The current study sought to establish the reliability, and basic
psychometric properties of a proposed composite cognitive endpointPsychometric characteristics of the MS-COG at Visits 1 and 2.
Statistic (Z scores) MS-COG: Visit 1
N = 59
MS-COG: Visit 2
N = 58
Mean −1.1 −0.75
Standard Deviation 1.3 1.1
Standard Error of the Mean 0.17 0.14
Range −4.1 to 1.3 −3.1 to 1.2
Skewness −0.37 −0.35
Kurtosis −0.61 −0.77
Table 6
Standard error of difference, retest effects, and cutoffs for 80% and 90% conﬁdence
intervals for factor scores and the MS-COG.
Index S Diff Retest effect
Learning and Memory Factor .69 .39
Information Processing Speed Factor .72 .48
MS-COG .55 .36
Table 8
Reliability coefﬁcients for the factor scores and MS-COG by MS subtype group.
Factor MS Type Pearson r
Information Processing Speed RR MS (n = 44) 0.88
SP MS (n = 14) 0.90
Learning and Memory RR MS (n = 44) 0.82
SP MS (n = 15) 0.91
MS-COG RR MS (n = 44) 0.90
SP MS (n = 14) 0.93
Table 9
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research on pharmaceutical interventions to treat CIAMS [1].
MS-COGdemonstrated high test–retest reliability of 0.91,whichwas
better than or similar to reports for the component subtests. MS-COG
endpoint also demonstrated a normal distribution with no evidence of
signiﬁcant skewness or kurtosis and a standard deviation close to that
of a non-impaired population (z = 1.3 for Visit 1; z = 1.1 for Visit 2)
which is an important feature for estimating sample sizes for large
pharmaceutical trials. Similarly, the standard error of the mean of the
MS-COG was small compared to the standard deviation, indicating
good potential for accuracy in assessment of each patient.
The psychometricmethodology for establishing the IPS and LMcom-
posites received preliminary support. Even in this small sample, factor
analysis identiﬁed two and only two factors which, upon inspection,
were comprised of the proposed component subtests in the respective
cognitive domains. Within each cognitive domain, the SDMT showed
somewhat greater sensitivity than PASAT and the BVMT-R showed
somewhat greater sensitivity than SRT. As these observations have
been reported in previous studies our conﬁdence was increased that
the data collected in the current study was representative of a typical
MS clinical sample.
The MS-COG identiﬁed 42% of MS patients from 4 US Clinics as hav-
ing clinically signiﬁcant cognitive impairment as indicated by a score
lower than 5% the comparison group of healthy participant, which is
similar to prevalence reported in clinical samples using other assess-
mentmethodologies [2–5]. Further, the IPS and LMcomposites revealed
sensitivities of 40% and 39%, respectively, which are similar to previous-
ly reported estimates [11,12]. Moreover, the frequency of impairment
identiﬁed by the MS-COG was maintained or increased modestly
relative to the LM and IPS composites, indicating that in this battery
multidimensional assessment is likely preferable to individual domains
for a pharmaceutical trial in which change in generalized cognitive
ability is of interest. However, it was clear that if a single domain of
impairment were of interest, individual measures such as the SDMT
and the BVMT-R would be expected to demonstrate greater sensitivity
within their respective domains in comparison to the domain-speciﬁc
IPS and LM composites. In this light, it is noted that ﬁndings of impair-
ment in multiple domains are preferable to single domains if the target
of a pharmaceutical intervention is a general cognitive impairment
syndrome and not a speciﬁc cognitive function. Further, the MS-COG
revealed greater frequency of impairment in patients with SP MS vs.
RR MS, in keeping with the greater disease severity associated with
the former population as documented in numerous research studies
[12,30,49].
In light of these strong psychometric properties, we believe that
choosing to use the MS-COG in a drug development clinical trial isTable 7
Severity and frequency of impairment by MS subtype for factor scores and the MS-COG.
Factor MS type Mean Z score
(SD)
% b −1.5
SD
Information
Processing Speed
RR MS (n = 44) −1.00 (1.5) 34
SP MS (n = 14) −1.85 (1.6) 62
Learning and Memory RR MS (n = 44) −0.96 (1.3) 33
SP MS (n = 15) −1.77 (1.5) 57
MS-COG RR MS (n = 44) −0.96 (1.2) 37
SP MS (n = 14) −1.75 (1.4) 62preferable to methodologies used in past drug studies. The MS-COG
also is preferable to the large battery of tests administered by Fischer
et al. [23] in English speaking subjects from the Avonex® Phase 3 trial
in regard to practicality, and also in regard to availability of alternate
forms and validation of component subtests. Further, the MS-COG has
psychometric support for the combination of component subtests
which was not the case in the Fischer et al., as that research which
was guided by clinical judgment, not a priori psychometric research.
We also believe that, given further research support and the speciﬁc na-
ture of the research question being investigated, the use of theMS-COG
might be preferred than the use of current clinical batteries such as the
MACFIMS [50] and BRB [51]. That is, while the MACFIMS would be ex-
pected to serve as a more robust comprehensive assessment in clinical
settings for characterization of neuropsychological status and for guid-
ing treatment and intervention as it provides assessment of 5 rather
than 2 domains, it is far lengthier—approximately 90 min vs. 30 min
for MS-COG-and has only one alternate form. Indeed, the limitation in
available alternate forms is especially salient in memory assessment,
indicating that the SRT with 3 alternate forms is greatly preferred to
the CVLT for a pharmaceutical trial with more than two assessments.
In this light, it is noted that 3 of the 4 tests included in the MS-COG
are included in the MACFIMS, identifying the MS-COG as an alternative
potentially more suitable for international multi-center pharmaceutical
trials in MS due to its relative brevity, repeatability, and its status as a
single outcome. Similarly, the MS-COG shares 3 of 4 measures with
BRB, although the latter was never developed for use as a single factor
outcome. In further support of the acceptability of the subtests compris-
ing the Composite is the selection of some of its components by both
BICAMS and the NINDS CDE Task Force [31]. Finally, the subtest compo-
nents of theMS-COG are easily administered by trained study personnel
and not just by neuropsychologists, facilitating feasibility in large inter-
national clinical trials. For example, in the current study, test adminis-
trators included trained and supervised psychology graduate students
and nurses as well as neuropsychologists.
The poor correlation between patient- and informant-reported neu-
ropsychological symptoms and objective performance on the MS-COG
was not unexpected as previous researchers have made similar obser-
vations [36]. Still, the current study was remarkable for two observa-
tions. First, RR MS subjects were clearly better able to perceive their
neuropsychological symptoms, as their self-appraisals weremoderately
correlated with their overall performance, whereas self-appraisals of SP
MS subjects consistently lacked meaningful association with their ownCorrelations between the MS-COG and symptom reports by MS type.
Subtest MS type r with composite
MFQ General Forgetting RR MS (n = 44) 0.39
SP MS (n = 15) −0.11
MSQOL (Physical Health) RR MS (n = 44) 0.44
SP MS (n = 15) −0.16
MSQOL (Mental Health) RR MS (n = 44) 0.35
SP MS (n = 15) −0.15
MSNQ-Patient RR MS (n = 44) −0.38
SP MS (n = 15) 0.13
MSNQ-Informant RR MS (n = 44) −0.40
SP MS (n = 15) −0.37
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assessment and insight into symptoms worsens with the severity of
cognitive impairment. Second, as has been noted previously, informants
can provide useful information regarding MS cognitive problems [36].
Particularly in regard to future studies of cognitively impaired SPMSpa-
tients, the current MFQ, MSQOL, and MSNQ ﬁndings can be interpreted
as strongly supportive of the preferential use of informant reports vs.
patient reports. These observations may be relevant and important in
guiding future research as patient- and/or informant-reported out-
comes are typically areas of interest to regulatory authorities.
In conclusion, based on the present results, we believe that the MS-
COG has a reasonably clear psychometric basis, sensitivity similar to a
larger and broader battery of tests, a normal distribution of scores, and
high test–retest reliability. We note, however, that these statements
are limited by the possibility that the results were distorted by the use
of demographic adjustments to scores from a single control group vs. a
normative database and may be limited in generalizability if MS
patients differ signiﬁcantly in regard to demographics. However, we
believe that making such demographic adjustments based on a single
normative source is preferable to use of multiple normative databases
so long as the two groups are relatively similar, which was the case
presently. We also note that the current retest effect may not be repre-
sentative as we did not counterbalance tests. We expect to investigate
this possibility as well as the implications for this in future research
efforts. We further note that future studies will be required to establish
reliabilities for multiple time points and longer test–retest intervals.
The reliability and sensitivity of the MS-COG endpoint may be affected
by such parameters. The composite endpoint is comprised of subtests
with available alternate forms and limited though supportive evidence
of cross-cultural utility, making it feasible for international trials [17,
52-61]. We believe that it is reasonable to proceed with proof-of-
concept-type trials for pharmaceutical interventions hypothesizing
cognitive beneﬁt using the MS-COG. However, it will be important for
such proof-of-concept studies to demonstrate further cross-cultural
utility and to clarify the clinical meaningfulness of any observed
changes as the current study did not employ any such pharmaceutical
intervention.
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